Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
That's also how I work it out, OVB owned 625,000 POLY shares after March 2020.
1,400,000 show in the AR 2018
630,000 sold in 2019 and 145,000 sold in the AR in Feb and Mar (1400000 - 775000 = 625000)
These are currently worth : £17.95 each = £11,218,750 or 12.75p per OVB share (88m shares undiluted)
That 12.75p is virtually the sp, so all the business is valued at zero. Maybe that's the true worth of our sexual dysfunction business, it's been a long time waiting to find out while the Directors spend the POLY divi's
Sold out of here yesterday to fund day trading on SNG. Managed to make a little profit but haven't put back in here yet.
Will definitely be keeping an eye on this though and hopefully will buy back in the future.
Bit of interest finally, maybe news on the drug tests or sold the rest of the gold, could start moving?
Gold soaring, huge interest in new drugs for new treatments and we sit where we are, how boring?
They started the year with 1.4m and subsequently sold 630,000
In February and March 2020, the Group, through its subsidiary, Silver Star Ltd., sold 145,000 shares of Polymetal 2.2m euros
24 March 2020, the Company’s subsidiary, Silver Star Ltd., acquired the remaining shareholding interest in IVIX LLC for a total cash consideration of €4.6m.
They had 10.2m Euros cash at year end so 2.4m to make up above purchase. Add in 630k shares and about 21.6p a share : 81.5m shares if you exclude treasury shares: cash and equivalents, 14m euros tax losses and probably paid over 10p a share for IVIX.
Will multibag once go ahead given.
I saw they sold down 630k in 2019, taking their holding at 31.12.19 to 1.4mn. But where did you read in the AR that they sold a further 145k?
They sold 630k during 2019 and a further 145k in Feb and March but also have a decent cash pile.
Makes for interesting reading.
NAV 27p per share. Held 1.4mn shares of Polymetal at 31.12.19. No indication that any more have been sold since the b/s date, so if these are still held, they are valued today at £21mn, which is 26p/sh alone.
A deep value play but of course cash + investments will be required over time to support the company's Clinical trial development plans. We now know that the first Western market will be Australia, later this year, for a P2 trial. Wonder why not Germany?
seems we pulled back a little with the market. To add or not to add.
There should be an update on the medical trials, well overdue?
Yes, indeed so - I notice the lowest ASK on show is now back up to 12.5p, with very close to that actually being paid.
Rewards ahead for holding, I trust!
Yep getting closer each day to the major news items here. Underpinned by cash/liquid assets of more than the current SP.
:-)
This is one of those drugs that will suddenly explode into the market and we will wonder how we forgot to invest. Absolute winner when it happens. Soon please!
Yep fast money is in and out of this one but will get caught out at some point.
Pure value play with some nice big catalysts approaching. Great level to accumulate
A slow burner value story, this one. The fast money hasn't got it going, so I presume they've been leaning on the stock yesterday and today. Now is the time to pick some up cheaply.
Sure they would have sold a few more to fund the final purchase of 40.9% of IVIX.
Total of 11.1 dollars paid.
Add Poly shares.
Market cap of between £18/20 at lowest estimate.
737k is the last known amount
Not 100% sure but would guess still holding around 600.000.
And with Poly shares gainging around £5.50 since year end 31st Dec.
Plus nice dividend payments.
Anyone know how many POLY shares they have left?
OVB has been showing support at 5.13 and resistance at 13.25. Moving averages are rising, There is bullish indication in MACD, Stochastic oscillator and RSI.
http://www.stoxline.com/uk/stockuk.php?s=ovb
I am interested in ovb, from a value pov. Love the Poly share holding. But I have to admit that the Russian angle puts me off a lot and I don't think I'm alone in that. Do you know any more about the Individual Russians involved? Are they expats in the UK?
Poly shares are so going great guns & have been towing OVB along.
Need some news on progression of operations from OVB to really get this share moving.
What’s currently on offer is a drug candidate which has been through phase 3 trials in Russia and is now at Advanced marketing application phase PLUS €16.5m in cash and liquid assets. ALL FOR UNDER £10M. You are looking at the investment and adding additional funding requirements which don’t exist.
Older and wiser. All good questions but the fact still remains cash and liquid assets above market cap with no value whatsoever ascribed to the HSDD drug that they have paid $10m for? You can look for catches and relative costs for Trials and approval In the EU but facts are facts. Good effort though ;)